- Home
- SHOT vs CUE Comparison
SHOT vs CUE Comparison
Compare SHOT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- CUE
- Stock Information
- Founded
- SHOT 2018
- CUE 2014
- Country
- SHOT United States
- CUE United States
- Employees
- SHOT N/A
- CUE N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- CUE Health Care
- Exchange
- SHOT Nasdaq
- CUE Nasdaq
- Market Cap
- SHOT 62.8M
- CUE 64.4M
- IPO Year
- SHOT 2020
- CUE 2018
- Fundamental
- Price
- SHOT $0.95
- CUE $1.25
- Analyst Decision
- SHOT
- CUE Strong Buy
- Analyst Count
- SHOT 0
- CUE 5
- Target Price
- SHOT N/A
- CUE $5.00
- AVG Volume (30 Days)
- SHOT 709.7K
- CUE 971.4K
- Earning Date
- SHOT 11-26-2024
- CUE 11-14-2024
- Dividend Yield
- SHOT N/A
- CUE N/A
- EPS Growth
- SHOT N/A
- CUE N/A
- EPS
- SHOT N/A
- CUE N/A
- Revenue
- SHOT $180,174.00
- CUE $9,532,000.00
- Revenue This Year
- SHOT N/A
- CUE $104.81
- Revenue Next Year
- SHOT N/A
- CUE N/A
- P/E Ratio
- SHOT N/A
- CUE N/A
- Revenue Growth
- SHOT 68.01
- CUE 149.53
- 52 Week Low
- SHOT $0.55
- CUE $0.45
- 52 Week High
- SHOT $7.50
- CUE $3.25
- Technical
- Relative Strength Index (RSI)
- SHOT 39.44
- CUE 43.10
- Support Level
- SHOT $0.91
- CUE $1.32
- Resistance Level
- SHOT $1.20
- CUE $1.99
- Average True Range (ATR)
- SHOT 0.09
- CUE 0.29
- MACD
- SHOT -0.01
- CUE -0.06
- Stochastic Oscillator
- SHOT 13.49
- CUE 0.67
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.